WealthTrust Asset Management LLC Invests $48,000 in Sight Sciences, Inc. (NASDAQ:SGHT)

WealthTrust Asset Management LLC purchased a new position in Sight Sciences, Inc. (NASDAQ:SGHT) during the fourth quarter, HoldingsChannel reports. The firm purchased 13,200 shares of the company’s stock, valued at approximately $48,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Sight Sciences by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 268,250 shares of the company’s stock valued at $976,000 after buying an additional 11,259 shares during the last quarter. Stoneridge Investment Partners LLC purchased a new position in shares of Sight Sciences in the 4th quarter valued at approximately $55,000. SG Americas Securities LLC raised its position in shares of Sight Sciences by 47.6% in the 4th quarter. SG Americas Securities LLC now owns 17,622 shares of the company’s stock valued at $64,000 after purchasing an additional 5,681 shares during the last quarter. KCK LTD. purchased a new position in shares of Sight Sciences in the 4th quarter valued at approximately $15,925,000. Finally, Arkadios Wealth Advisors purchased a new position in shares of Sight Sciences in the 4th quarter valued at approximately $47,000. 55.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SGHT shares. Stifel Nicolaus cut their price target on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Citigroup cut their price target on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Piper Sandler dropped their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. UBS Group dropped their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a research note on Monday, January 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Thursday, March 6th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.83.

Insider Transactions at Sight Sciences

In related news, CEO Paul Badawi sold 12,236 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total value of $44,049.60. Following the sale, the chief executive officer now directly owns 5,713,197 shares in the company, valued at approximately $20,567,509.20. The trade was a 0.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Manohar K. Raheja acquired 10,000 shares of Sight Sciences stock in a transaction that occurred on Wednesday, March 12th. The stock was bought at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the acquisition, the executive vice president now owns 145,000 shares in the company, valued at $395,850. This trade represents a 7.41 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 63,014 shares of company stock worth $197,295 in the last quarter. Company insiders own 28.90% of the company’s stock.

Sight Sciences Price Performance

Sight Sciences stock opened at $2.72 on Friday. The company’s fifty day moving average price is $2.80 and its 200 day moving average price is $4.25. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock has a market capitalization of $139.63 million, a P/E ratio of -2.67 and a beta of 2.52. Sight Sciences, Inc. has a 1 year low of $2.17 and a 1 year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). The firm had revenue of $19.07 million during the quarter, compared to analysts’ expectations of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same quarter in the previous year, the business posted ($0.22) EPS. As a group, equities research analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.